Free Stipulation - District Court of Delaware - Delaware

Case 1:07-cv-00457-SLR

Document 72

Filed 07/25/2008

Page 1 of 3

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE CANCER RESEARCH TECHNOLOGY LIMITED and, SCHERING CORPORATION, Plaintiff, v. BARR LABORATORIES, INC. and BARR PHARMACEUTICALS, INC., Defendants. ) ) ) ) ) ) Civil Action No. 07-457 (SLR) ) ) ) ) ) ) )

STIPULATION NOT TO CONTEST INFRINGEMENT IT IS HEREBY STIPULATED, CONSENTED, AND AGREED TO by and between the parties hereto as follows: 1. Plaintiffs Cancer Research Technology Limited ("CRT") and Schering

Corporation ("Schering") (collectively "Plaintiffs") and defendants Barr Laboratories, Inc. and Barr Pharmaceuticals, Inc. (collectively, "Barr") are parties to this patent infringement case involving U.S. Patent No. 5,260,291 ("the `291 patent"). 2. Barr stipulates that the commercial use or sale of the drug products

described in ANDA No. 78-879 and the Amendment to ANDA No. 78-879 infringe claims 1, 3, 5-7, 11-13, and 27 of the `291 patent, if valid and enforceable, under 35 U.S.C. § 271. Barr's stipulation of infringement is not intended to limit or otherwise affect Barr's ability to defend against Plaintiffs' infringement claims on any other ground, including, but not limited to, asserting defenses of invalidity and/or unenforceability of claims 1, 3, 5-7, 11-13, and 27 of the `291 patent.

Case 1:07-cv-00457-SLR

Document 72

Filed 07/25/2008

Page 2 of 3

3.

Plaintiffs will not seek discovery from Barr directed solely to the issue of

infringement of the `291 patent with respect to the issues of this case. Plaintiffs reserve the right to take any and all discovery directed to any other issue in the case. 4. Plaintiffs will not assert that the commercial manufacture, use, sale, offer

for sale, or importation of the drug products presently set forth and described in ANDA No. 78879 and the Amendment to ANDA No. 78-879 infringe any claim of the `291 patent, except claims 1, 3, 5-7, 11-13, and 27. 5. Plaintiffs and Barr reserve all rights to appeal any decision of this Court

with respect to the issues of validity and/or enforceability of claims 1, 3, 5-7, 11-13, and 27 of the `291 patent, and the entry of any such judgment as it pertains to validity and/or unenforceability of those claims. 6. of the `291 patent. CONSENTED TO: Dated: July 25, 2008 MORRIS, NICHOLS, ARSHT & TUNNELL LLP PHILLIPS, GOLDMAN & SPENCE, P.A. Plaintiffs withdraw with prejudice their claim of infringement of claim 2

/s/ Rodger D. Smith II
_________________________________________ Jack B. Blumenfeld (#1014) Rodger D. Smith II (#3778) 1201 N. Market Street Wilmington, DE 19899-1347 (302) 658-9200 [email protected] Attorneys for Plaintiffs Cancer Research Technology Limited and Schering Corporation

/s/ John C. Phillips, Jr.
____________________________________ John C. Phillips, Jr. (#110) Brian E. Faman (#4089) 1200 North Broom Street Wilmington, DE 19806 (302) 655-4200 [email protected] Attorneys for Defendants Barr Laboratories, Inc. and Barr Pharmaceuticals, Inc.

2

Case 1:07-cv-00457-SLR

Document 72

Filed 07/25/2008

Page 3 of 3

OF COUNSEL: Jesse J. Jenner Denise L. Loring Christopher J. Harnett Matthew Traupman ROPES & GRAY LLP 1211 Avenue of the Americas New York, NY 10036 (212) 596-9000

OF COUNSEL: George C. Lombardi Taras A. Gracey Ivan M. Poullaos Julia Mano Johnson WINSTON & STRAWN LLP 35 West Wacker Drive Chicago, IL 60601 (312) 558-5600

APPROVED, ORDERED and ENTERED this _____ day of _________________, 2008.

______________________________ United States District Judge

3